Seres Therapeutics Inc (MCRB)

Seres Therapeutics' stock price has decreased by 44.72% over the past six months and by 48.3% year-to-date as of May 9, 2026. In Q4 and Full Year 2025, the company reported a net income of $5.7 million for 2025 and had $45.8 million in cash, expecting to fund operations through Q3 2026. In Q1 2026, Seres reported a net loss of $19.9 million and held $29.8 million in cash, expecting to fund operations through Q3 2026. The company is expected to need additional capital raises, which could lead to dilution for current investors. Positive feedback from the FDA regarding its Phase 2 plan for SER-155 and efforts to secure a partnership for SER-155 are seen as strengthening the company's growth prospects, with upcoming clinical data readouts for SER-155 in immune checkpoint inhibitor-related enterocolitis anticipated in Q2 2026.

Direct demand seasonality is not explicitly detailed for Seres Therapeutics' products and services. The demand for these therapies would likely be driven more by disease incidence, clinical trial progress, and regulatory approvals rather than strong seasonal fluctuations, with the exception of potential seasonal variations in respiratory infections for allo-HSCT patients.

Seres Therapeutics is a clinical-stage biotechnology company focused on developing live biotherapeutics to treat inflammatory and immune diseases by restoring the function of a disrupted microbiome. The company focuses on microbiome therapeutics, developing biological drugs to modulate or restore healthy microbial communities. Seres led the development and FDA approval of VOWST™, the first orally administered microbiome therapeutic for the prevention of recurrent Clostridioides difficile infection (CDI), but this product was divested to Nestlé Health Science. The company's pipeline includes SER-155 for preventing bacterial bloodstream infections in allo-HSCT patients, SER-603 for inflammatory bowel disease, and SER-287, SER-301, and SER-401 for ulcerative colitis and other inflammatory conditions.

Seres Therapeutics is headquartered in Cambridge, Massachusetts, United States. The company conducts multi-center clinical trials across North America and Europe.

Seres Therapeutics has maintained its reputation as a clinical-stage biotechnology company focused on microbiome therapeutics. The successful development and FDA approval of VOWST™, followed by its sale to Nestlé Health Science, demonstrated the company's capability in bringing a novel microbiome therapeutic to market. The company has been actively presenting preclinical and clinical data for its pipeline candidates, including SER-603 and SER-155. Leadership changes included the appointment of Richard N. Kender as Executive Chair and interim Chief Executive Officer.

Seres Therapeutics has a mixed ownership structure. Individual investors hold a substantial 52% stake, with retail investors holding approximately 77.22% of the company's stock. Institutional investors hold approximately 13.17% to 25.47% of the company's stock, with major holders including Flagship Pioneering Inc., Vanguard Group Inc., and BlackRock, Inc. Insiders hold approximately 1.07% to 12.62% of the stock.